Gene Editing to
Revolutionize Biotech

October 28, 2022

C4U and Brain Research Institute, Niigata University have entered into the collaborative research agreement for a novel gene therapy utilizing CRISPR -Cas3 technology.

September 1, 2022

The paper “Dynamic mechanisms of CRISPR interference by Escherichia coli CRISPR-Cas3” was published in Nature Communications.

August 31, 2022

In addition to the current collaborative research and alliance agreement, C4U and Sumitomo Pharma identified additional target cells and genes for two regenerative medicine products respectively, and entered into a collaborative research and alliance agreement for each of them. These brought the total number of our collaborative research and alliance agreement between C4U and Sumitomo Pharma to three.

June 29, 2022

C4U and Logomix have entered into the joint research agreement on applying CRISPR-Cas3 genome editing technology to Logomix's Geno-WritingTM technology.

June 3, 2022

C4U and the Center for iPS Cell Research and Application(CiRA), Kyoto University have conducted a joint research since January 2020 to promote the research utilizing novel genome editing technology over iPS cells.
For the further expansion of this joint research, on May 30, 2022, C4U, CiRA and CiRA Foundation entered into a new collaborative research agreement for the purpose of the "research on genome editing for clinical iPS cells utilizing CRISPR-Cas3 technology".

©2019 C4U Corporation